Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
Oncolytics Biotech announced a new method of use patent covering pelareorep as a cancer immunotherapy issued in several countries, with U.S. issuance expected in the near term. The company has three patent application families pending and plans to convert one to a U.S. Track One prioritized examination this quarter, targeting a final disposition within about 12 months of prioritized status.
Key figures
- Expected protection extension
- late 2040s
- Patients dosed with pelareorep
- 1200
- Pending patent application families
- 3
- Manufacturing patent protection through
- 2044
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.